anticholinergic agent

Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.

Related to anticholinergic agent: antispasmodic agent, adrenergic agent

an·ti·cho·lin·er·gic a·gent

(antē-kō-li-nĕrjik ājĕnt)

Drug that inhibits action of acetylcholine or cholinergic drugs at cholinergic receptors.
Synonym(s): cholinergic blocking agent.

agent

1. any power, principle or substance by which something is accomplished, or which is capable of producing a chemical, physical or biological effect such as a disease.

2. of disease; any factor whose excessive presence or relative absence is essential for the occurrence of a disease.

adrenergic neuron blocking agent

one that inhibits the release of norepinephrine from postganglionic adrenergic nerve endings.

alkylating agent

a cytotoxic agent, e.g. a nitrogen mustard, which is highly reactive and can donate an alkyl group to another compound. Alkylating agents inhibit cell division by reacting with DNA and are used as antineoplastic agents.

anesthetic agent

substance capable of producing reversible general or local anesthesia.

anticholinergic agent

cholinergic blocking agent.

agent change

change in an animal's chemical or antigenic configuration can alter its pathogenicity. For example, a case of nitrate-nitrite poisoning in a cow can become a case of nitrite poisoning after conversion of the nitrate in the rumen. Mutation and antigenic drift are other types of change that vary agent pathogenicity.

chelating agent

a compound that combines with metals to form weakly dissociated complexes in which the metal is part of a ring, and is used to extract certain elements from a system.

chemical agent

substance that produces change by virtue of its chemical composition and its effects on living tissues and organisms.

cholinergic blocking agent

one that blocks the action of acetylcholine at nicotinic or muscarinic receptors of nerves or effector organs.

determinant agent

only some agents are determinants of diseases in that they always cause disease, and the same disease, and the disease does not occur without the agent. Many agents require the intervention of other factors, such as anaerobicity of tissue, hepatic insufficiency or physiological stress before they can establish their pathogenicity.

ganglionic blocking agent

one that blocks cholinergic transmission at autonomic ganglionic synapses.

immobilizing agent

see neuromuscular blockade.

infectious agent

an organism able to live in or on the tissue of a living animal; may not necessarily cause disease.

agent interaction

is the interaction between precipitating and predisposing causes of disease.

oxidizing agent

a substance that acts as an electron acceptor in a chemical oxidation-reduction reaction.

agent properties

are the properties which determine the pathogenicity of the agent, the solubility and acidity or biodegradability of a chemical, the virulence, adhesiveness, resistance to antibacterial agents of bacteria and viruses and so on.

reducing agent

a substance that acts as an electron donor in a chemical oxidation-reduction reaction.

surface-active agent

a substance that exerts a change on the surface properties of a liquid, especially one, such as a detergent, that reduces its surface tension. Called also surfactant.

therapeutic agent

a substance capable of producing a curative effect in a disease state.

agent without disease

exemplified by the orphan viruses. The agent is of a type that causes disease, but none is associated with the presence of the particular agent.

References in periodicals archive ?

Fesoterodine is an anticholinergic agent comparable to darifenacin, with similar mechanism of action and advertised therapeutic effects.

A review of Anticholinergic medications for overactive bladder symptoms

There are currently 5 anticholinergic agents approved by the US Food and Drug Administration (FDA) for the treatment of overactive bladder (OAB): oxybutynin, toherodine, trospium, solifenacin, and, most recently, darifenacin.

Adverse cognitive effects of anticholinergic therapy: treating OAB in geriatric patients

1]-antagonist diphenhydramine, the anticholinergic agent atropine, the glucocorticosteroid budesonide, or the bradykinin [B.

Effects of inhaled brevetoxins in allergic airways: toxin-allergen interactions and pharmacologic intervention

Hays LL: The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent.

Craniofacial hyperhidrosis successfully treated with topical glycopyrrolate

Undoubtedly, if a patient with OAB is successfully managed with behavioural therapy and a single first-line anticholinergic agent, the cost to the health care system is less than repeated treatments with BTX A.

Botulinum toxin A should not be first-line therapy for overactive bladder

Conflicting results have been found on the question of whether the bronchodilator effect of [beta] agonists is increased by adding an anticholinergic agent, in either COPD or asthma.

Anticholinergic bronchodilators: different solution to the same problem

1-3) An alternative agent is the short-acting anticholinergic agent ipratropium bromide, which is sometimes used either on its own or in combination with SABA.

It is important to recognise the inflammatory nature of asthma

Possible overdose with an anticholinergic agent such as a tricyclic antidepressant or a variety of mushroom.

Diagnostic dilemma

9 mg daily of the antispasmodic anticholinergic agent.

Oxytrol Patch. (New & Approved)

For a patient who is conscious, a better alternative anticholinergic agent is intravenous glycopyrrolate.

Simple measures for dying patients can limit secretions, death rattle

This anticholinergic agent, which blocks the muscarinic acetylcholine receptor in the lung and reduces mucus secretion without systemic absorption or side effects, is useful in those with moderate and severe asthma when given along with the first nebulized dose of a bronchodilator such as albuterol, Dr.

Consider both old and new treatments for acute asthma. (Making the Right Choice)

In a randomized, placebo-controlled, crossover trial, 21 cognitively intact elderly persons were given doses of placebo or Artane (trihexyphenidyl), a muscarinic anticholinergic agent with documented adverse effects on diverse cognitive functions.

Apolipoprotein [epsilon]4 confers general brain vulnerability: Consequences include faster brain aging. (Sensitivity to Drug Effects)